LP Therapeutics

LP Therapeutics is a clinical-stage biopharmaceutical company focused on developing advanced oncology treatments using its proprietary Lipid-Polymer Technology (LPT) platform. The company specializes in the reformulation of proven chemotherapeutic agents into sophisticated liposomal delivery systems designed to improve drug stability, enhance tumor targeting, and minimize systemic side effects. Its lead candidate, LPT-01, is a liposomal formulation of irinotecan currently in clinical development for the treatment of pancreatic and colorectal cancers. Beyond its lead program, the company is advancing a pipeline of liposomal taxanes, including LPT-02 (docetaxel) and LPT-05 (paclitaxel), targeting various solid tumors. Headquartered in Singapore with research facilities in France, LP Therapeutics leverages a global network to accelerate the delivery of more effective and safer cancer therapies to patients.